KRT20 Antikörper (AA 196-323)
Kurzübersicht für KRT20 Antikörper (AA 196-323) (ABIN7871723)
Target
Alle KRT20 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 196-323
-
Verwendungszweck
- Cytokeratin 20 Antibody / CK20 / KRT20
-
Aufreinigung
- Protein G affinity chromatography
-
Immunogen
- A portion of amino acids 196-323 from the human protein was used as the immunogen for this Cytokeratin 20 antibody.
-
Isotyp
- IgG1, kappa
-
-
-
-
Applikationshinweise
-
Optimal dilution of the Cytokeratin 20 antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min. -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- Prediluted in 1X PBS, 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide, *For IHC use only*
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store the Cytokeratin 20 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
-
-
- KRT20 (Keratin 20 (KRT20))
-
Andere Bezeichnung
- Cytokeratin 20
-
Hintergrund
- This mAb recognizes an intermediate filament protein of 46 kDa, identified as Cytokeratin 20 (KRT20, CK20). KRT is abundantly expressed in goblet cells and enterocytes of the gastrointestinal tract. It is a useful marker of pancreatic and colorectal cancer. KRT20 is expressed under normal, hyperplastic and neoplastic conditions. It has been detected in adenocarcinomas of the colon, stomach and biliary tract. Breast carcinomas are generally non-reactive.
-
UniProt
- P35900
Target
-